AIMS/HYPOTHESIS: An association between resting heart rate and mortality has been described in the general population and in patients with cardiovascular disease. There are, however, few data exploring this relationship in patients with type 2 diabetes mellitus. The current study addresses this issue. METHODS: The relationship between baseline resting heart rate and all-cause mortality, cardiovascular death and major cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) was examined in 11,140 patients who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Study. RESULTS: A higher resting heart rate was associated with a significantly increased risk of all-cause mortality (fully adjusted HR 1.15 per 10 bpm [95% CI 1.08, 1.21], p<0.001), cardiovascular death and major cardiovascular outcomes without adjustment and after adjusting for age and sex and multiple covariates. The increased risk associated with a higher baseline resting heart rate was most obvious in patients with previous macrovascular complications (fully adjusted HR for death 1.79 for upper [mean 91 bpm] vs lowest [mean 58 bpm] fifth of resting heart rate in this subgroup [95% CI 1.28, 2.50], p = .001). CONCLUSIONS/ INTERPRETATION: Among patients with type 2 diabetes, a higher resting heart rate is associated with an increased risk of death and cardiovascular complications. It remains unclear whether a higher heart rate directly mediates the increased risk or is a marker for other factors that determine a poor outcome.
AIMS/HYPOTHESIS: An association between resting heart rate and mortality has been described in the general population and in patients with cardiovascular disease. There are, however, few data exploring this relationship in patients with type 2 diabetes mellitus. The current study addresses this issue. METHODS: The relationship between baseline resting heart rate and all-cause mortality, cardiovascular death and major cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) was examined in 11,140 patients who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Study. RESULTS: A higher resting heart rate was associated with a significantly increased risk of all-cause mortality (fully adjusted HR 1.15 per 10 bpm [95% CI 1.08, 1.21], p<0.001), cardiovascular death and major cardiovascular outcomes without adjustment and after adjusting for age and sex and multiple covariates. The increased risk associated with a higher baseline resting heart rate was most obvious in patients with previous macrovascular complications (fully adjusted HR for death 1.79 for upper [mean 91 bpm] vs lowest [mean 58 bpm] fifth of resting heart rate in this subgroup [95% CI 1.28, 2.50], p = .001). CONCLUSIONS/ INTERPRETATION: Among patients with type 2 diabetes, a higher resting heart rate is associated with an increased risk of death and cardiovascular complications. It remains unclear whether a higher heart rate directly mediates the increased risk or is a marker for other factors that determine a poor outcome.
Authors: Xavier Jouven; Jean-Philippe Empana; Peter J Schwartz; Michel Desnos; Dominique Courbon; Pierre Ducimetière Journal: N Engl J Med Date: 2005-05-12 Impact factor: 91.245
Authors: H V Huikuri; V Jokinen; M Syvänne; M S Nieminen; K E Airaksinen; M J Ikäheimo; J M Koistinen; H Kauma; A Y Kesäniemi; S Majahalme; K O Niemelä; M H Frick Journal: Arterioscler Thromb Vasc Biol Date: 1999-08 Impact factor: 8.311
Authors: Radim Jurca; Andrew S Jackson; Michael J LaMonte; James R Morrow; Steven N Blair; Nicholas J Wareham; William L Haskell; Willem van Mechelen; Timothy S Church; John M Jakicic; Raija Laukkanen Journal: Am J Prev Med Date: 2005-10 Impact factor: 5.043
Authors: C Stettler; A Bearth; S Allemann; M Zwahlen; L Zanchin; M Deplazes; E R Christ; A Teuscher; P Diem Journal: Diabetologia Date: 2006-11-10 Impact factor: 10.122
Authors: Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams Journal: Lancet Date: 2007-09-08 Impact factor: 79.321
Authors: Kim Fox; Jeffrey S Borer; A John Camm; Nicolas Danchin; Roberto Ferrari; Jose L Lopez Sendon; Philippe Gabriel Steg; Jean-Claude Tardif; Luigi Tavazzi; Michal Tendera Journal: J Am Coll Cardiol Date: 2007-08-13 Impact factor: 24.094
Authors: Magnus T Jensen; Mette Wod; Søren Galatius; Jacob B Hjelmborg; Gorm B Jensen; Kaare Christensen Journal: Heart Date: 2017-06-21 Impact factor: 5.994
Authors: Catherine L Stables; David S Auerbach; Steven E Whitesall; Louis G D'Alecy; Eva L Feldman Journal: Auton Neurosci Date: 2015-12-17 Impact factor: 3.145
Authors: Sareh Keshavarzi; Barbara H Braffett; Rodica Pop-Busui; Trevor J Orchard; Elsayed Z Soliman; Gayle M Lorenzi; Annette Barnie; Amy B Karger; Rose A Gubitosi-Klug; Samuel Dagogo-Jack; Andrew D Paterson Journal: Diabetes Care Date: 2021-02-25 Impact factor: 19.112